國家衛生研究院 NHRI:Item 3990099045/12230

NHRI > National Institute of Infectious Diseases and Vaccinology > Shih-Jen Liu > Periodical Articles > Item 3990099045/12230

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/12230

Title:	Endoplasmic reticulum-targeting sequence enhanced the cellular immunity of a tumor-associated antigen L6-based DNA vaccine
Authors:	Sher, YP;Lin, SI;Chai, KM;Chen, IH;Liu, SJ
Contributors:	National Institute of Infectious Diseases and Vaccinology
Abstract:	Cancer vaccine design to effectively eliminate tumors requires triggering strong immune reactions to elicit long-lasting humoral and cellular immunity and DNA vaccines have been demonstrated to be an attractive immunotherapeutic approach. The tumor-associated antigen L6 (TAL6) is overexpressed on the surface of different cancer cells and promotes cancer progression; therefore, it could be a potential target for cancer treatment. We have revealed that a synthetic peptide containing HLA-A2-restricted cytotoxic T lymphocyte (CTL) and B cell epitope can induce cellular and humoral immunity against TAL6-expressing cancer. To enhance the efficacy of immunotherapy, in this report, we designed an endoplasmic reticulum (ER)-targeting sequence (adenovirus E3/19K protein) at the N-terminus of TAL6 to facilitate MHC class I antigen presentation to CD8(+) T cells. Transfection of mammalian cells with the plasmid containing TAL6 fused with the ER-targeting sequence (pEKL6) resulted in higher levels of TAL6 antigens in the ER than transfection with the full-length TAL6 (pL6). The plasmid pEKL6 induced both TAL6-specific CTL responses and antibody titers after intramuscular (IM) immunization with electroporation and it elicited higher levels of antigen-specific CTLs in HLA-A2 transgenic mice. Immunization with pEKL6 induced higher levels of protective antitumor immunity against tumor growth than pL6 immunization in thymoma and melanoma tumor animal models. Notably, pEKL6 elicited long-term anti-tumor immunity against the recurrence of cancers. We found that CD4(+) T, CD8(+) T, and NK cells are all important for the effector mechanisms of pEKL6 immunization. Thus, cancer therapy using an ER-targeting sequence linked to a tumor antigen holds promise for treating tumors by triggering strong immune reactions.
Date:	2019-09-01
Relation:	American Journal of Cancer Research. 2019 Sep 1;9(9):2028-2036.
Link to:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6780668/
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2156-6976&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000488234300013
Appears in Collections:	[Shih-Jen Liu] Periodical Articles

Files in This Item:

File	Description	Size	Format
ISI000488234300013.pdf		1165Kb	Adobe PDF	293	View/Open

Loading...